Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Itamar Raz

Showing results (11-20 of 310) with videos related to

Pageof 31
Sort By:
The Israel Medical Association Journal : IMAJ|July 13, 2006
Metabolic syndrome and microangiopathyAuryan Szalat, Itamar Raz
Diabetes Care|April 29, 2011
Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugsBoaz Hirshberg, Itamar Raz
Diabetes/Metabolism Research and Reviews|December 17, 2011
Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarmsItamar Raz, Roy Eldor
Diabetes Care|February 15, 2008
The Controversies in Obesity, Diabetes and Hypertension (CODHy) meeting: what is it all about?Itamar Raz, Ram Weiss
The Review of Diabetic Studies : RDS|June 27, 2009
The Individualized Target HbA1c: A New Method for Improving Macrovascular Risk and Glycemia Without Hypoglycemia and Weight GainRoy Eldor, Itamar Raz
Women'S Health (London, England)|October 7, 2009
Gender-specific care of diabetesAuryan Szalat, Itamar Raz
Diabetes Care|November 24, 2016
Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets? Diabetes Care 2016;38:e145-e146Itamar Raz, Avivit Cahn
Diabetes/Metabolism Research and Reviews|July 18, 2020
NAFLD in type 2 diabetes mellitus: Still many challenging questionsSimona Cernea, Itamar Raz
The Review of Diabetic Studies : RDS|January 21, 2012
The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS special issueItamar Raz, Baptist Gallwitz
Diabetes Care|April 29, 2011
Therapy in the early stage: incretinsSimona Cernea, Itamar Raz
Pageof 31

Showing results (11-20 of 310) with videos related to

Sort By:
Pageof 31
The Israel Medical Association Journal : IMAJ|July 13, 2006
Metabolic syndrome and microangiopathyAuryan Szalat, Itamar Raz
Diabetes Care|April 29, 2011
Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugsBoaz Hirshberg, Itamar Raz
Diabetes/Metabolism Research and Reviews|December 17, 2011
Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarmsItamar Raz, Roy Eldor
Diabetes Care|February 15, 2008
The Controversies in Obesity, Diabetes and Hypertension (CODHy) meeting: what is it all about?Itamar Raz, Ram Weiss
The Review of Diabetic Studies : RDS|June 27, 2009
The Individualized Target HbA1c: A New Method for Improving Macrovascular Risk and Glycemia Without Hypoglycemia and Weight GainRoy Eldor, Itamar Raz
Women'S Health (London, England)|October 7, 2009
Gender-specific care of diabetesAuryan Szalat, Itamar Raz
Diabetes Care|November 24, 2016
Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets? Diabetes Care 2016;38:e145-e146Itamar Raz, Avivit Cahn
Diabetes/Metabolism Research and Reviews|July 18, 2020
NAFLD in type 2 diabetes mellitus: Still many challenging questionsSimona Cernea, Itamar Raz
The Review of Diabetic Studies : RDS|January 21, 2012
The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS special issueItamar Raz, Baptist Gallwitz
Diabetes Care|April 29, 2011
Therapy in the early stage: incretinsSimona Cernea, Itamar Raz
Pageof 31